301 related articles for article (PubMed ID: 21328340)
21. Augmentation of invadopodia formation in temozolomide-resistant or adopted glioma is regulated by c-Jun terminal kinase-paxillin axis.
Ueno H; Tomiyama A; Yamaguchi H; Uekita T; Shirakihara T; Nakashima K; Otani N; Wada K; Sakai R; Arai H; Mori K
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):240-7. PubMed ID: 26518652
[TBL] [Abstract][Full Text] [Related]
22. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
23. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Wang Y; Gao S; Wang W; Liang J
Mol Med Rep; 2016 Dec; 14(6):5732-5738. PubMed ID: 27878252
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of ILK promotes temozolomide resistance in glioma cells.
Liang F; Wang B; Bao L; Zhao YS; Zhang SM; Zhang SQ
Mol Med Rep; 2017 Mar; 15(3):1297-1304. PubMed ID: 28138714
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Ohba S; Hirose Y; Kawase T; Sano H
J Neurooncol; 2009 Dec; 95(3):307-316. PubMed ID: 19517066
[TBL] [Abstract][Full Text] [Related]
28. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
[TBL] [Abstract][Full Text] [Related]
29. Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
Wang Q; Du J; Xu B; Xu L; Wang X; Liu J; Wang J
Acta Biochim Biophys Sin (Shanghai); 2016 Jun; 48(6):501-8. PubMed ID: 27189511
[TBL] [Abstract][Full Text] [Related]
30. Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Sai K; Li WY; Chen YS; Wang J; Guan S; Yang QY; Guo CC; Mou YG; Li WP; Chen ZP
Am J Chin Med; 2014; 42(2):485-503. PubMed ID: 24707876
[TBL] [Abstract][Full Text] [Related]
31. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
[TBL] [Abstract][Full Text] [Related]
32. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM
Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Fan TY; Wang H; Xiang P; Liu YW; Li HZ; Lei BX; Yu M; Qi ST
Int J Clin Exp Pathol; 2014; 7(10):6662-70. PubMed ID: 25400745
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
[TBL] [Abstract][Full Text] [Related]
35. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Gratas C; Séry Q; Rabé M; Oliver L; Vallette FM
Oncotarget; 2014 May; 5(9):2428-35. PubMed ID: 24811082
[TBL] [Abstract][Full Text] [Related]
36. The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Lu XY; Cao K; Li QY; Yuan ZC; Lu PS
J Int Med Res; 2012; 40(3):995-1004. PubMed ID: 22906272
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
Kumar DM; Patil V; Ramachandran B; Nila MV; Dharmalingam K; Somasundaram K
Proteomics; 2013 Jul; 13(14):2113-24. PubMed ID: 23595970
[TBL] [Abstract][Full Text] [Related]
38. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Han J; Chen Q
Int J Clin Exp Pathol; 2015; 8(10):12698-707. PubMed ID: 26722459
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Zhou Y; Wang HD; Zhu L; Cong ZX; Li N; Ji XJ; Pan H; Wang JW; Li WC
Oncol Rep; 2013 Jan; 29(1):394-400. PubMed ID: 23128449
[TBL] [Abstract][Full Text] [Related]
40. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Gong A; Ge N; Yao W; Lu L; Liang H
Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]